XML 59 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stock-based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Stock-based compensation expense recognized in each category of the consolidated statements of operations for the years ended December 31, 2023, 2022 and 2021 was as follows (in thousands):
 Year Ended December 31,
 202320222021
Veterinary invoice expense$3,667 $4,145 $4,538 
Other cost of revenue1,612 2,339 2,610 
Technology and development2,846 4,742 3,056 
General and administrative17,717 12,831 8,862 
New pet acquisition expense7,319 9,336 9,160 
Total expensed stock-based compensation33,161 33,393 28,226 
Capitalized stock-based compensation2,135 1,633 676 
Total stock-based compensation$35,296 $35,026 $28,902 
As of December 31, 2023, the Company had 714,382 unvested restricted stock units. Stock-based compensation expense of $44.6 million related to unvested restricted stock units are expected to be recognized over a weighted average period of approximately 2.4 years.
In March 2023, two executives terminated employment with the Company and one executive signed a separation agreement effective June 1, 2023. In conjunction with these departures, the Company accelerated the vesting of certain RSUs as of the termination date and extended the purchase date of certain vested options from 90 to 365 days. These award modifications resulted in the recognition of $4.8 million share-based compensation expense during the year ended December 31, 2023.
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
Stock Options
The grant date fair value of stock option awards are estimated on the date of grant using the Black-Scholes option-pricing model. The Company did not grant any new stock options during the years ended December 31, 2023, 2022, and 2021.
Schedule of Share-based Compensation, Stock Options, Activity
The following table presents information regarding stock options granted, exercised and forfeited for the periods presented:
Number
of
Options		Weighted Average
Exercise
Price per Share		Aggregate
Intrinsic
Value
(in thousands)
Outstanding as of January 1, 20211,459,290 $9.93 $160,200 
Granted— — — 
Exercised(647,164)5.59 58,200 
Forfeited(4,921)13.66 — 
Outstanding as of December 31, 2021807,205 13.39 95,765 
Granted— — — 
Exercised(174,721)12.82 10,931 
Forfeited(2,834)18.87 — 
Outstanding as of December 31, 2022629,650 13.53 21,410 
Granted— — — 
Exercised(213,848)12.47 3,720 
Forfeited(6,832)12.80 — 
Outstanding as of December 31, 2023408,970 14.09 6,715 
Exercisable at December 31, 2023408,970 $14.09 $6,715 
As of December 31, 2023, stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 2.5 years.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]
The fair value of options vested were as follows for the years ended December 31, 2023, 2022, and 2021. The Company didn't grant any stock options in these three years.
Fair Value of Options Vested
(in thousands)
Year:
2021$313 
2022$— 
2023$— 
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
A summary of the Company’s restricted stock award and restricted stock unit activity for the years ended December 31, 2023, 2022 and 2021 is as follows:
Number of 
Shares		Weighted Average
Grant Date Fair Value per
Share
Unvested shares as of January 1, 2021782,755 $34.81 
Granted787,730 101.32 
Vested(426,725)40.10 
Forfeited(56,133)72.93 
Unvested shares as of December 31, 20211,087,627 78.94 
Granted623,401 84.11 
Vested(516,077)72.81 
Forfeited(82,399)81.91 
Unvested shares as of December 31, 20221,112,552 84.46 
Granted366,870 26.77 
Vested(669,413)72.52 
Forfeited(95,627)79.60 
Unvested shares as of December 31, 2023714,382 $66.64